Lung Cancer

3 barriers to liquid biopsy adoption in routine clinical practice

Evidence is growing for the use of circulating tumour DNA assays in early detection and monitoring of cancers, but three major barriers stand in the way of its adoption in clinical practice, Australian experts believe. A national workshop of almost 100 oncology researchers and industry representatives held in October 2020 concluded that issues such as ...

Already a member?

Login to keep reading.

© 2021 the limbic